Trial Profile
EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms STRIVE
- 04 Nov 2022 Results presented at The Obesity Society: ObesityWeek 2022
- 29 Apr 2021 Planned End Date changed from 28 Feb 2022 to 30 Jun 2022.
- 29 Apr 2021 Planned primary completion date changed from 31 Mar 2021 to 30 Jun 2022.